SCHEMBL8009451

SCHEMBL8009451

CCNS(=O)(=O)c1ccc(N2N=C(C)/C(=C/Nc3ccccc3OCC)C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.47
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 5/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
HSD17B10 Q99714 1/20 0.44
NPSR1 Q6W5P4 1/20 0.42
KAT8 Q9H7Z6 2/20 0.40
MDM4 O15151 1/20 0.40
MDM2 Q00987 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
MEN1 O00255 4/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 3/20 0.39
AMY1A P0DUB6 1/20 0.39
POLB P06746 1/20 0.39
CYP1A2 P05177 2/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6951766 1.00 PTGS2 (0.47) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL8428159 0.95 PTGS2 (0.46) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL6950419 0.89 PTGS2 (0.60) PTGS2ALDH1A1KMT2AL3MBTL1NPSR1
SCHEMBL6950421 0.89 PTGS2 (0.60) PTGS2ALDH1A1KMT2AL3MBTL1NPSR1
SCHEMBL6942495 0.88 PTGS2 (0.47) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL6942491 0.88 PTGS2 (0.47) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL9525776 0.87 ALDH1A1 (0.53) PTGS2ALDH1A1KMT2AL3MBTL1NPSR1
SCHEMBL6950175 0.87 KAT8 (0.42) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL6950173 0.87 KAT8 (0.42) PTGS2ALDH1A1KMT2AL3MBTL1HSD17B10
SCHEMBL6949542 0.86 PTGS2 (0.47) PTGS2ALDH1A1KMT2AL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6034099-A Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones CELL PATHWAYS, INC. (US) 2000-03-07 US disclosed
EP-0930881-A1 PYRAZOLINONES TO TREAT DISTURBANCES OF POTENCY MERCK PATENT GmbH (DE) 1999-07-28 EP disclosed
WO-1998016224-A1 PYRAZOLINONES TO TREAT DISTURBANCES OF POTENCY MERCK PATENT GMBH (DE) 1998-04-23 WO disclosed